Amrn conversations
The European approval was granted in March 2021, so revenue results have yet to reflect the potential of the European market. They are expected to exceed $650 million in 2021. Last year Vascepa sales, Amarin’s main revenue source, were up 42% to $607 million. and Europe to treat patients with high LDL-cholesterol and severe hypertriglyceridemia, conditions associated with increased risk of stroke, heart attack, and heart disease. Many of its treatments are based on omega-3 fatty acid which is an essential oil our bodies aren’t able to produce.Īmarin has the only drug on the market called Vascepa. (AMRN) is a commercial-stage pharmaceutical company focused on cardiovascular disease. Headquartered in Dublin, Ireland, Amarin Corp. The next two are up-and-coming OTC penny stocks. The first two, AMRN and AVXL trade on the Nasdaq.
Today we highlight four of the most intriguing biotech stocks generating buzz across social media platforms. Here at Insider Financial, we have a keen interest in the biotech space because the life-changing nature of its products can translate to life-changing gains for investors. Risk-seeking investors have also been rotating out of struggling cryptocurrencies and into biotech. However, the gap has closed considerably in the last few weeks thanks to some big biotech headlines including the FDA’s controversial approval of Biogen’s Alzheimer’s disease treatment. Their processes are typically based on some form of genetic analysis and engineering.Īs a group biotechnology stocks are up approximately 8% this year which lags the broader S&P 500 year-to-date return of 12.5%. The biotech industry includes a range of companies that research, develop, manufacture, and market therapies to treat human diseases. With the markets seemingly back in “risk-on” mode volatile biotechnology stocks have been among the biggest movers and shakers. All 11 sector groups advanced to start the week, a sign of broad-based market strength. The Dow Jones Industrial Average had its best day in more than three months on Monday with cyclical energy, industrial, financial, and transport stocks leading the way. It didn’t take long for investors to get over the Fed’s forecast for interest rate hikes by 2023 which rattled the markets late last week.Ĭoncerns of inflation and sooner than expected rate increases have largely subsided allowing the major averages to climb higher. biotech stocks are off to a strong start this week.